Novo Nordisk quits small molecules

Chynoweth, Emma
January 2007
ICIS Chemical Business;1/22/2007, Vol. 2 Issue 50, p30
Trade Publication
The article reports on the move made by Novo Nordisk AS to refocus its research and development efforts in order to concentrate on its growing pipeline of protein-based pharmaceuticals. Some of the firm's pipeline of products are given including treatment for diabetes, haemostasis and growth disorders. Information on the core competencies of the company is also presented.


Related Articles

  • Novo Nordisk commits to Chinese market.  // European Pharmaceutical Executive;May/Jun2006, p12 

    The article reports that Denmark-based Novo Nordisk is expanding its production facilities in Tianjin, China. This involves an assembly plant for its NovoPen 3 insulin pen and packaging facilities for its Penfill insulin cartridges and FlexPen prefilled insulin pens. The plant aims to meet the...

  • Novo Nordisk plans Tianjin insulin.  // TCE: The Chemical Engineer;Dec2008/Jan2009, Issue 810/811, p14 

    The article reports on the plan of pharmaceutical company Novo Nordisk to build a $400 million insulin production plant in Tianjin, China. The chemical plant will be constructed next to the company's existing Tianjin insulin production base. It will be the company's primary production base for...

  • Chain Pharmacy: REPORTER'S NOTEBOOK.  // Drug Store News;4/19/2004, Vol. 26 Issue 6, p29 

    Reports developments related to pharmaceutical industry in the U.S. Launch of ReliOn/Novolin InnoLet Human Insulin prefilled insulin doser from Novo Nordisk Pharmaceuticals; Introduction of national advertising campaign publicizing its senior savings program and investment in pharmaceutical...

  • News in brief.  // Nature Reviews Drug Discovery;Mar2010, Vol. 9 Issue 3, p181 

    The article offers news briefs from the pharmaceutical industry in the U.S. Food & Drug Administration (FDA) in the U.S. has approved Novo Nordisk A/S created drug peptide 1 (GLP1) analogue liraglutide. Pharmaceutical companies including Pfizer Inc. and GlaxoSmithKline have announced...

  • CLINIC ROUNDUP.  // BioWorld Today;12/8/2009, Vol. 20 Issue 235, p8 

    This section offers news briefs on the pharmaceutical industry as of December 2009. AEterna Zentaris Inc. reported that primary endpoint has not been reached in the Phase III results for the European efficacy trial of Z-036 for treating benign prostatic hyperplasia. Novo Nordisk A/S has...

  • FDA actions in brief.  // Formulary;Oct2005, Vol. 40 Issue 10, p322 

    Reports on U.S. Food and Drug Administration actions regarding various drugs. Approval of an influenza vaccine from GlaxoSmithKline; Approval of a combination vaccine from Merck; Approval of an insulin aspart injection from Novo Nordisk; Approval of atorvastatin from Pfizer.

  • NEW DELIVERY.  // Drug Topics;11/21/2005, Vol. 149 Issue 22, p51 

    This article reports that Novo Nordisk AS' NovoLog already has clearance for intravenous administration, under proper medical supervision in a clinical setting.

  • Pipeline.  // Pharmaceutical Representative;Oct2011, Vol. 41 Issue 10, p10 

    The article presents news briefs on the pharmaceutical industry, in 2011. Positive safety and efficacy data has been reported by Tarsa Therapeutics, from its Phase III ORACAL trial of Ostora. Details on Amgen Inc.'s new long-term data on Prolia (denosumab) treatment, are presented. Novo Nordisk...

  • '08 STEALTH PHARMAS.  // Pharmaceutical Executive;Jun2008, Vol. 29 Issue 6, p58 

    The article presents the Stealth Pharma review of the 12 drug companies in the U.S. Stealth Pharma is considered as a difficult grab-category that evaluates and audit the small pharmaceutical companies specializing in biotech, generics and orphan drugs. These companies include Allergan Inc.,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics